Amy­lyx's ALS treat­ment Re­lyvrio fails PhI­II study, biotech to con­sid­er with­draw­ing drug

Re­lyvrio, Amy­lyx’s FDA-ap­proved ALS drug, has failed a cru­cial Phase III tri­al, the com­pa­ny said on Fri­day, a ma­jor blow to what had been con­sid­ered one of the few sig­nif­i­cant op­tions avail­able for the treat­ment of the dead­ly neu­rode­gen­er­a­tive dis­ease.

The fail­ure is al­most cer­tain to put ac­cess to the drug in jeop­ardy, and Amy­lyx said it would con­sid­er with­draw­ing the drug.

In new Phase III tri­al da­ta re­leased Fri­day study­ing 664 ALS pa­tients, Amy­lyx’s drug failed to out­per­form a place­bo. The drug al­so missed all sec­ondary out­comes, which in­clud­ed qual­i­ty-of-life ques­tion­naires, as­sess­ing the spread of the dis­ease, and mus­cle func­tion. The p-val­ue on the tri­al’s main goal was 0.667, a high­ly non-sta­tis­ti­cal­ly sig­nif­i­cant re­sult.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER